PerkinElmer

NOVEMBER 9, 2022

Immunotherapy has revolutionized cancer treatment and proved to be pivotal in the field of oncological research. While certain patients respond to these therapies, antibody drugs have some natural drawbacks such as poor oral bioavailability, poor permeability of tumor tissues, immune-related adverse events, and high medical costs.

Small Molecule 52

Small Molecule Research Immune Response FDA Approval 52

New Drug Approvals

SEPTEMBER 29, 2024

link] 01 Aug 2022 Cortexyme is now called Quince Therapeutics You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. gingivalis is associated with cardiovascular disease. and Europe.

Small Molecule 62

Small Molecule DNA Disease Trials 62

The Pharma Data

JANUARY 13, 2021

Preliminary analyses showed no clinically meaningful differences in safety results between the dexpramipexole and placebo groups, with no serious adverse events and 96% of subjects completing the primary assessment phase. Background standard of care was inhaled corticosteroids in combination with a long-acting ?2 President and CEO of Knopp.

Trials 52

Trials Small Molecule Clinical Trials Treatment 52

The Pharma Data

MARCH 28, 2022

Tomorrow, Sanofi will host an Immunology Investor Event with key members of the leadership team providing updates on how the company is advancing its Immunology strategy, including the ambition to more than quadruple Immunology franchise sales by the end of the decade. A broad Phase 1 clinical program of small molecules and biologics.

Small Molecule 52

Small Molecule Clinical Development Disease Science 52

The Pharma Data

AUGUST 18, 2020

Johnson & Johnson statement on the launch of new CARE (Corona Accelerated R&D in Europe) consortium, Europe’s largest, multi-partner scientific research initiative dedicated to discovering and developing urgently needed treatment options for COVID-19. Small molecule discovery. Virus-neutralizing antibody discovery.

Treatment 52

Treatment Pharmaceutical Companies Research Small Molecule 52

The Pharma Data

JANUARY 26, 2021

Food and Drug Administration’s Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B , a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. (OTCQB: QBIO), announced today that the U.S. .

FDA 40

FDA Treatment Small Molecule Drugs 40

The Pharma Data

AUGUST 30, 2021

The study will allow assessment of any difference in efficacy that may persist at month 6 of treatment. A larger percentage of patients treated with abrocitinib 200mg experienced adverse events compared to dupilumab 300mg. There were no cases of malignancies or venous thromboembolism (VTE) events confirmed through adjudication.

Small Molecule 52

Small Molecule Trials Treatment FDA 52

KIF1A

AUGUST 20, 2024

In fact the Yellow Brick Road Project, representing patients with HNRNPH2 mutations, dubbed this the Year of the Pioneer, a banner we’re happy to spread: It reflects the unknown course of navigating a disorder and its treatments, the vulnerability, and the bravery required to risk dangerous lands for a chance at safer havens.

Science 52

Science Treatment Therapies Small Molecule 52

The Pharma Data

NOVEMBER 8, 2021

“HER-MES is the first study that directly compared the therapeutic effects of an antibody and a small molecule in migraine prevention,” said Uwe Reuter, M.D., “The positive outcomes strengthen the efficacy and safety profile of erenumab as a migraine prevention treatment for patients with migraine.”

Therapies 52

Therapies FDA Approval Treatment Small Molecule 52

The Pharma Data

DECEMBER 15, 2020

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. BUFFALO, N.Y.,

FDA Approval 52

FDA Approval FDA Treatment Small Molecule 52

New Drug Approvals

DECEMBER 16, 2023

2 On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. 5 Iptacopan , sold under the brand name Fabhalta , is a medication used for the treatment of paroxysmal nocturnal hemoglobinuria. [1] 1] It is a complement factor B inhibitor that was developed by Novartis. [1]

FDA 62

FDA Small Molecule FDA Approval Treatment 62

Drug Target Review

JUNE 12, 2023

With 13 preclinical candidates and three AI-designed drugs currently undergoing clinical trials, Insilico is spearheading a revolution in cancer treatment and beyond. Can you provide a summary of the key findings and implications of the preclinical studies on ISM6331 for the treatment of advanced solid tumours?

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Pharmacokinetics 92

New Drug Approvals

JANUARY 31, 2024

Sotuletinib (BLZ945) is an experimental drug in development for the treatment of amyotrophic lateral sclerosis (ALS). “Emerging clinical investigational drugs for the treatment of amyotrophic lateral sclerosis” Expert Opinion on Investigational Drugs. 36 (1): 456–467. 32 (2): 141–160.

Small Molecule 52

Small Molecule Virus Treatment Disease 52

The Pharma Data

OCTOBER 14, 2020

operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications. About VBL Vascular Biogenics Ltd., Source link.

Treatment 52

Treatment Clinical Trials Small Molecule Trials 52

The Pharma Data

NOVEMBER 29, 2020

1 Meanwhile, these MDM2 inhibitors present some challenges, including dose-limiting hematological toxicities, thus the urgent need to develop new generation of MDM2-targeting therapies in the treatment of cancer. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment.

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

JANUARY 31, 2021

Convergent is currently conducting advanced human trials relating to prostate cancer treatments involving peptide receptor radionuclide therapy (“PRRT”) that targets the prostate-specific membrane antigen (“PSMA”) present on prostate cancer cells. and foreign patents.

Small Molecule 52

Small Molecule FDA Approval Therapies Trials 52

Advarra

FEBRUARY 24, 2023

But what does “working” really mean when efficacy means something subjective, like quality of life, reduced psychiatric events, or less symptoms? Also known as a clinical event committee (CEC), EAC members evaluate a clinical event in the context of the protocol and the individual participant’s medical information.

Clinical Trials 52

Clinical Trials Trials FDA Therapies 52

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. The principle of TPD is to use small molecules to commit the target protein into the E3 ligase-mediated degradation pathway thereby eliminating or reducing its activity.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

NOVEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. , (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

Small Molecule 40

Small Molecule Clinical Trials Production Treatment 40

Drug Target Review

JULY 7, 2023

In pregnant individuals, maternal autoantibodies can even attack the organs and tissues of the foetus, 1-9 Many of these diseases are rare, with no safe, targeted, advanced and effective treatment options approved for patients in need. By stopping or blocking the normal work of these molecules, diseases can often be slowed or even stopped.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

OCTOBER 27, 2020

Mirati Therapeutics is a San Diego -based late-stage biotechnology company relentlessly focused on translating drug discovery and research into new treatments for patients by advancing and delivering novel therapeutics that target the genetic and immunologic drivers of cancer. About Mirati Therapeutics. SOURCE Mirati Therapeutics, Inc.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

MARCH 4, 2021

Our goal is to one day bring new treatment options that provide greater seizure control, tolerability and function to DS and LGS patients around the world.”. Advancing New Treatment Options for DS and LGS Patients. Lennox-Gastaut syndrome can be caused by a variety of underlying conditions, but in some cases no cause can be identified.

Treatment 52

Treatment Clinical Trials Pharmaceutical Companies Trials 52

The Pharma Data

OCTOBER 1, 2021

Pfizer today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved CIBINQO ® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with inadequate response to existing therapies.

Clinical Trials 52

Clinical Trials Small Molecule Trials Treatment 52

The Pharma Data

DECEMBER 10, 2020

We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible.”. LX9211 is a potent, orally delivered, selective small molecule inhibitor of adapter-associated kinase 1 (AAK1). About LX9211. Source link.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

Agency IQ

JUNE 9, 2023

Even so, nonclinical studies are generally expected to be complete prior to the initiation of Phase 3 clinical studies in which the product is evaluated in much larger human populations and/or for longer periods of treatment. Nonclinical studies encompass much more than just animal studies.

FDA 40

FDA Small Molecule Science Immune Response 40

The Pharma Data

AUGUST 29, 2020

Phase II results are promising for treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder; 1,2 second Phase II study with LNP023 monotherapy in anti-C5 naïve PNH patients ongoing . All patients required RBC transfusions prior to starting LNP023 treatment. “In Peffault de Latour.

Treatment 52

Treatment Disease Small Molecule Production 52

The Pharma Data

OCTOBER 25, 2020

Roxadustat is approved for the treatment of anemia associated with CKD in Japan in dialysis dependent patients and in China in both dialysis dependent and non-dialysis dependent patients. In the study, the drug demonstrated statistically significant and clinically meaningful efficacy and a favorable adverse event and tolerability profile.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

JANUARY 13, 2021

There remains a significant need for new treatments with improved activity and tolerability to prevent or treat organ transplant rejection and to treat autoimmune conditions, including systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis.”. 1 Lederman, S. Also, etanercept (Enbrel®) is a TNF?

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

JANUARY 3, 2021

As compared to treatment with cabozantinib, the combination of telaglenastat and cabozantinib did not meet the primary endpoint of improving progression free survival (PFS) in the study population. The frequency and severity of adverse events in the telaglenastat-treated population were comparable to that of cabozantinib alone. “We

Trials 52

Trials Clinical Trials Small Molecule Therapies 52

Elrig

JUNE 4, 2024

Zahra Jawad is the founder and CEO of Creasallis, a company focused on antibody remodeling to improve penetration and treatment of solid tumours. The focus used to be more on small molecules, but we’re now starting to see antibody and cell therapeutics. Have you attended ELRIG before?

Small Molecule 52

Small Molecule Science Drugs Research 52

The Pharma Data

OCTOBER 26, 2020

AR-711 was previously shown to be effective in prophylactic as well as therapeutic treatment modes in a SARS-CoV-2 viral challenge study. AR-711 is currently being developed as an inhaled, self-administered treatment for non-hospitalized patients suffering from mild to moderate COVID-19. About Aridis Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

OCTOBER 21, 2020

“We look forward to advancing clinical development of KB-0742 to establish the dose, safety and efficacy of this investigational therapy as a potential treatment for MYC-amplified tumors.”. The current treatment for prostate cancer consists of targeting AR activity, a key driver of prostate cancer. “The

Clinical Trials 40

Clinical Trials Small Molecule Treatment Clinical Development 40

The Pharma Data

JANUARY 7, 2021

ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist in late-stage clinical development for recurrent gliomas that harbor the H3 K27M mutation. An archived webcast will be available on the Chimerix website approximately two hours after the event.

Clinical Trials 52

Clinical Trials Small Molecule Trials Therapies 52

The Pharma Data

DECEMBER 8, 2020

Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 8,110,000 shares of its common stock at a price to the public of $37.00 SAN DIEGO, Dec.

Small Molecule 52

Small Molecule Clinical Trials Treatment Trials 52

The Pharma Data

JULY 15, 2021

“Several high impact Victorian healthcare collaborations have been signed since our launch, including those novel medical technologies and treatments for neurodegenerative and autoimmune conditions, and solutions for significant unmet needs in global public health including maternal mortality and infectious diseases.”

Government 52

Government Science Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

OCTOBER 18, 2020

Despite recent advances in the targeted treatment of AML, the majority of patients will relapse or remain refractory to current therapies and there remains a significant unmet need for new therapies. About CG-806. Forward Looking Statements. This press release contains forward-looking statements within the meaning of Canadian and U.S.

Small Molecule 40

Small Molecule Clinical Trials Trials Therapies 40

The Pharma Data

NOVEMBER 12, 2020

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. LEXINGTON, Mass., 12, 2020 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. About Keros Therapeutics, Inc.

Clinical Trials 40

Clinical Trials Small Molecule Treatment Production 40